DNA binding partners of YAP/TAZ

키워드

참고문헌 (98)

1. Saucedo LJ, "Filling out the Hippo pathway", Nat Rev Mol Cell Biol, 8, pp.613~621 (2007)[DOI]
2. Harvey K, "The Salvador-Warts-Hippo pathway - an emerging tumour-suppressor network", Nat Rev Cancer, 7, pp.182~191 (2007)[DOI]
3. Zhao B, "Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control", Genes Dev, 21, pp.2747~2761 (2007)[DOI]
4. Camargo FD, "YAP1 increases organ size and expands undifferentiated progenitor cells", Curr Biol, 17, pp.2054~2060 (2007)[DOI]
5. Dong J, "Elucidation of a universal size-control mechanism in Drosophila and mammals", Cell, 130, pp.1120~1133 (2007)[DOI]
6. Huang J, "The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila Homolog of YAP", Cell, 122, pp.421~434 (2005)[DOI]
7. Fang KS, "A transmembrane protein-tyrosine phosphatase contains spectrin-like repeats in its extracellular domain", J Biol Chem, 269, pp.14056~14063 (1994)
8. Zhu C, "The regulation and function of YAP transcription co-activator", Acta Biochim Biophys Sin (Shanghai), 47, pp.16~28 (2015)[DOI]
9. Sudol M, "Characterization of the mammalian YAP (Yes-associated protein) gene and its role in defining a novel protein module, the WW domain", J Biol Chem, 270, pp.14733~14741 (1995)[DOI]
10. Kanai F, "TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins", EMBO J, 19, pp.6778~6791 (2000)[DOI]
11. Morin-Kensicki EM, "Defects in yolk sac vasculogenesis, chorioallantoic fusion, and embryonic axis elongation in mice with targeted disruption of Yap65", Mol Cell Biol, 26, pp.77~87 (2006)[DOI]
12. Hall CA, "Hippo pathway effector Yap is an ovarian cancer oncogene", Cancer Res, 70, pp.8517~8525 (2010)[DOI]
13. Wang Y, "Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer", Cancer Sci, 101, pp.1279~1285 (2010)[DOI]
14. Zhou Z, "RNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901", Hepatogastroenterology, 58, pp.2156~2161 (2011)
15. Chan SW, "TEADs mediate nuclear retention of TAZ to promote oncogenic transformation", J Biol Chem, 284, pp.14347~14358 (2009)[DOI]
16. Yu FX, "Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling", Cell, 150, pp.780~791 (2012)[DOI]
17. Mo JS, "Regulation of the Hippo-YAP pathway by proteaseactivated receptors (PARs)", Genes Dev, 26, pp.2138~2143 (2012)[DOI]
18. Liu-Chittenden Y, "Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP", Genes Dev, 26, pp.1300~1305 (2012)[DOI]
19. Zhao B, "Both TEAD-binding and WW domains are required for the growth stimulation and oncogenic transformation activity of yes-associated protein", Cancer Res, 69, pp.1089~1098 (2009)
20. Zhang H, "Yes-associated protein (YAP) transcriptional coactivator functions in balancing growth and differentiation in skin", Proc Natl Acad Sci U S A, 108, pp.2270~2275 (2011)[DOI]
21. Strano S, "Physical interaction with Yes-associated protein enhances p73 transcriptional activity", J Biol Chem, 276, pp.15164~15173 (2001)[DOI]
22. Komuro A, "WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus", J Biol Chem, 278, pp.33334~33341 (2003)[DOI]
23. Zagurovskaya M, "EGR-1 forms a complex with YAP-1 and upregulates Bax expression in irradiated prostate carcinoma cells", Oncogene, 28, pp.1121~1131 (2009)[DOI]
24. Qiao Y, "RUNX3 is a novel negative regulator of oncogenic TEAD-YAP complex in gastric cancer", Oncogene, 35, pp.2664~2674 (2016)[DOI]
25. Yagi R, "A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator", EMBO J, 18, pp.2551~2562 (1999)[DOI]
26. Ferrigno O, "Yes-associated protein (YAP65) interacts with Smad7 and potentiates its inhibitory activity against TGF-beta", Smad signaling, 2002, pp.21, 4879~4884
27. Kurisaki A, "Transforming growth factor-beta induces nuclear import of Smad3 in an importin-beta1 and Ran-dependent manner", Mol Biol Cell, 12, pp.1079~1091 (2001)[DOI]
28. Vassilev A, "TEAD", TEF transcription factors utilize the activation domain of YAP65, a Src, Genes Dev, pp.2001, 15[DOI]
29. Xiao JH, "Cloning, expression, and transcriptional properties of the human enhancer factor TEF-1", Cell, 65, pp.551~568 (1991)[DOI]
30. Kaneko KJ, "Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors", Dev Genet, 22, pp.43~55 (1998)[DOI]
31. Jacquemin P, "Differential expression of the TEF family of transcription factors in the murine placenta and during differentiation of primary human trophoblasts in vitro", Dev Dyn, 212, pp.423~436 (1998)[DOI]
32. Li Z, "Structural insights into the YAP and TEAD complex", Genes Dev, 24, pp.235~240 (2010)[DOI]
33. Chen L, "Structural and functional insights into the TEAD-YAP complex in the Hippo signaling pathway", Protein Cell, 1, pp.1073~1083 (2010)[DOI]
34. Zhao B, "TEAD mediates YAP-dependent gene induction and growth control", Genes Dev, 22, pp.1962~1971 (2008)[DOI]
35. Mo JS, "Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway", Nat Cell Biol, 17, pp.500~510 (2015)[DOI]
36. Zhao B, "The Hippo-YAP pathway: new connections between regulation of organ size and cancer", Curr Opin Cell Biol, 20, pp.638~646 (2008)[DOI]
37. Zhou Y, "The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis", Int J Mol Sci, 17, pp.1~15 (2016)
38. Hiemer SE, "The transcriptional regulators TAZ and YAP direct transforming growth factor beta-induced tumorigenic phenotypes in breast cancer cells", J Biol Chem, 289, pp.13461~13474 (2014)[DOI]
39. Rashidian J, "Ski regulates Hippo and TAZ signaling to suppress breast cancer progression", Sci Signal, 8, pp.ra14~ (2015)[DOI]
40. You B, "Inhibition of ERK1", 2 down-regulates the Hippo, Oncotarget, pp.2015, 6[DOI]
41. Nguyen LT, "ERG Activates the YAP1 Transcriptional Program and Induces the Development of Age-Related Prostate Tumors", Cancer Cell, 27, pp.797~808 (2015)[DOI]
42. Chan LH, "Hedgehog signaling induces osteosarcoma development through Yap1 and H19 overexpression", Oncogene, 33, pp.4857~4866 (2014)[DOI]
43. Zhang W, "Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma", Sci Signal, 7, pp.ra42~ (2014)[DOI]
44. Cai H, "The role of LPA and YAP signaling in long-term migration of human ovarian cancer cells", Cell Commun Signal, 11, pp.31~ (2013)[DOI]
45. Artinian N, "Phosphorylation of the Hippo Pathway Component AMOTL2 by the mTORC2 Kinase Promotes YAP Signaling, Resulting in Enhanced Glioblastoma Growth and Invasiveness", J Biol Chem, 290, pp.19387~19401 (2015)[DOI]
46. Yu FX, "Mutant Gq", 11 promote uveal melanoma tumorigenesis by activating YAP, 2014, pp.25, 822~830
47. Serrano I, "Inactivation of the Hippo tumour suppressor pathway by integrin-linked kinase", Nat Commun, 4, pp.2976~ (2013)
48. Wang J, "TRIB2 acts downstream of Wnt", TCF in liver cancer cells to regulate YAP and C, Mol Cell, pp.2013, 51[DOI]
49. Liu AM, "An update on targeting Hippo-YAP signaling in liver cancer", Expert Opin Ther Targets, 16, pp.243~247 (2012)[DOI]
50. Fernandez LA, "Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation", Oncogene, 31, pp.1923~1937 (2012)[DOI]
51. Fujii M, "Convergent signaling in the regulation of connective tissue growth factor in malignant mesothelioma: TGFbeta signaling and defects in the Hippo signaling cascade", Cell Cycle, 11, pp.3373~3379 (2012)[DOI]
52. Xia Y, "YAP", TEAD co-activator regulated pluripotency and chemoresistance in ovarian cancer initiated cells, 2014, pp.9, e109575~
53. Chen L, "Structural basis of YAP recognition by TEAD4 in the hippo pathway", Genes Dev, 24, pp.290~300 (2010)[DOI]
54. Fossdal R, "A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration)", Hum Mol Genet, 13, pp.975~981 (2004)[DOI]
55. Kitagawa M, "A Sveinsson's chorioretinal atrophyassociated missense mutation in mouse Tead1 affects its interaction with the co-factors YAP and TAZ", Biochem Biophys Res Commun, 361, pp.1022~1026 (2007)[DOI]
56. Zhang J, "YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway", Nat Cell Biol, 11, pp.1444~1450 (2009)[DOI]
57. Yang N, "TAZ induces growth factor-independent proliferation through activation of EGFR ligand amphiregulin", Cell Cycle, 11, pp.2922~2930 (2012)[DOI]
58. Neto-Silva RM, "Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap", Dev Cell, 19, pp.507~520 (2010)[DOI]
59. Li C, "Arsenic-induced cutaneous hyperplastic lesions are associated with the dysregulation of Yap, a Hippo signaling-related protein", Biochem Biophys Res Commun, 438, pp.607~612 (2013)[DOI]
60. Thongon N, "The GSK3beta inhibitor BIS I reverts YAP-dependent EMT signature in PDAC cell lines by decreasing SMADs expression level", Oncotarget, 7, pp.26551~26566 (2016)
61. Pobbati AV, "Emerging roles of TEAD transcription factors and its coactivators in cancers", Cancer Biol Ther, 14, pp.390~398 (2013)[DOI]
62. Zawacka-Pankau J, "p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach?", Cell Cycle, 9, pp.720~728 (2010)[DOI]
63. Basu S, "Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis", Mol Cell, 11, pp.11~23 (2003)[DOI]
64. Strano S, "The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage", Mol Cell, 18, pp.447~459 (2005)[DOI]
65. Oka T, "Mst2 and Lats kinases regulate apoptotic function of Yes kinaseassociated protein (YAP)", J Biol Chem, 283, pp.27534~27546 (2008)[DOI]
66. Rossi M, "The ubiquitin-protein ligase Itch regulates p73 stability", EMBO J, 24, pp.836~848 (2005)[DOI]
67. Levy D, "The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73", Cell Death Differ, 14, pp.743~751 (2007)[DOI]
68. Lapi E, "PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop", Mol Cell, 32, pp.803~814 (2008)[DOI]
69. Bernassola F, "Ubiquitin-dependent degradation of p73 is inhibited by PML", J Exp Med, 199, pp.1545~1557 (2004)[DOI]
70. Okazaki T, "Upregulation of endogenous PML induced by a combination of interferon-beta and temozolomide enhances p73", YAPmediated apoptosis in glioblastoma, 2012, pp.323, 199~207
71. Cottini F, "Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers", Nat Med, 20, pp.599~606 (2014)[DOI]
72. Levy D, "Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage", Mol Cell, 29, pp.350~361 (2008)[DOI]
73. Keshet R, "c-Abl antagonizes the YAP oncogenic function", Cell Death Differ, 22, pp.935~945 (2015)[DOI]
74. Rosenbluh J, "beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis", Cell, 151, pp.1457~1473 (2012)[DOI]
75. Zaidi SK, "Tyrosine phosphorylation controls Runx2-mediated subnuclear targeting of YAP to repress transcription", EMBO J, 23, pp.790~799 (2004)[DOI]
76. Omerovic J, "Ligand-regulated association of ErbB-4 to the transcriptional co-activator YAP65 controls transcription at the nuclear level", Exp Cell Res, 294, pp.469~479 (2004)[DOI]
77. Haskins JW, "Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration", Sci Signal, 7, pp.ra116~ (2014)[DOI]
78. Schuchardt BJ, "Molecular basis of the binding of YAP transcriptional regulator to the ErbB4 receptor tyrosine kinase", Biochimie, 101, pp.192~202 (2014)[DOI]
79. Aqeilan RI, "Loss of WWOX expression in gastric carcinoma", Clin Cancer Res, 10, pp.3053~3058 (2004)[DOI]
80. Aqeilan RI, "Association of Wwox with ErbB4 in breast cancer", Cancer Res, 67, pp.9330~9336 (2007)[DOI]
81. Aqeilan RI, "The WWOX tumor suppressor is essential for postnatal survival and normal bone metabolism", J Biol Chem, 283, pp.21629~21639 (2008)[DOI]
82. Aqeilan RI, "WW domain-containing proteins, WWOX and YAP, compete for interaction with ErbB-4 and modulate its transcriptional function", Cancer Res, 65, pp.6764~6772 (2005)[DOI]
83. Del Mare S, "Tumor Suppressor WWOX inhibits osteosarcoma metastasis by modulating RUNX2 function", Sci Rep, 5, pp.12959~ (2015)[DOI]
84. Das A, "Ionizing radiation down-regulates p53 protein in primary Egr-1-", - mouse embryonic fibroblast cells causing enhanced resistance to apoptosis, 2001, pp.276, 3279~3286
85. Murakami M, "A WW domain protein TAZ is a critical coactivator for TBX5, a transcription factor implicated in Holt-Oram syndrome", Proc Natl Acad Sci U S A, 102, pp.18034~18039 (2005)[DOI]
86. Derynck R, "Smad-dependent and Smad-independent pathways in TGF-beta family signalling", Nature, 425, pp.577~584 (2003)[DOI]
87. Varelas X, "TAZ controls Smad nucleocytoplasmic shuttling and regulates human embryonic stem-cell self-renewal", Nat Cell Biol, 10, pp.837~848 (2008)[DOI]
88. Varelas X, "The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway", Dev Cell, 19, pp.831~844 (2010)[DOI]
89. Grannas K, "Crosstalk between Hippo and TGFbeta: Subcellular Localization of YAP", TAZ, J Mol Biol, pp.2015, 427[DOI]
90. Komori T, "Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts", Cell, 89, pp.755~764 (1997)[DOI]
91. Otto F, "Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development", Cell, 89, pp.765~771 (1997)[DOI]
92. Marzia M, "Decreased c-Src expression enhances osteoblast differentiation and bone formation", J Cell Biol, 151, pp.311~320 (2000)[DOI]
93. Soriano P, "Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice", Cell, 64, pp.693~702 (1991)[DOI]
94. Hong JH, "TAZ, a transcriptional modulator of mesenchymal stem cell differentiation", Science, 309, pp.1074~1078 (2005)[DOI]
95. Li QL, "Causal relationship between the loss of RUNX3 expression and gastric cancer", Cell, 109, pp.113~124 (2002)[DOI]
96. Jang JW, "RAC-LATS1", 2 signaling regulates YAP activity by switching between the YAP-binding partners TEAD4 and RUNX3, 2017, pp.36, 999~1011
97. Zender L, "Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach", Cell, 125, pp.1253~1267 (2006)[DOI]
98. Barry ER, "Restriction of intestinal stem cell expansion and the regenerative response by YAP", Nature, 493, pp.106~110 (2013)

관련 논문AI추천